# Post–Week 39 bounded Phase 2 recommendation

## Purpose

This note records the **next disciplined scheduling posture** after week **39** so planning does not default to **momentum-driven churn** on the closed **evidence quality workspace** (**`evidence_quality_workspace_v1`**, **`GET /api/v1/evidence-quality-workspace`**, **`view=evidence-quality-workspace`**), **evidence weakness explanation** (**`evidence_weakness_explanation_v1`**, **`GET /api/v1/evidence-weakness-explanation`**), **cross-surface pivots** (topology, policies, services, maintenance, stability, investigation, path, change safety, NOC, global operator search, operator briefing, Overview), or **verifier / test** anchors—each remains **contract-bounded** read-side work with explicit non-claims.

**Phase:** [`Phase 2 — read-only product foundation`](../../agent/sdn/01-CURRENT-PHASE.md) — **unchanged** unless explicit new evidence supports a documented phase-boundary review.

## What week 39 closed

Week **39** is **closed** as a bounded Phase **2** **innovation** lane—documented in [`../../agent/sdn/03-CURRENT-STATUS.md`](../../agent/sdn/03-CURRENT-STATUS.md) **Week 39 closure (Friday rollup)** and aligned with:

- **Contracts:** [`evidence-quality-workspace-contract.md`](./evidence-quality-workspace-contract.md); [`evidence-weakness-explanation-contract.md`](./evidence-weakness-explanation-contract.md)
- **APIs:** **`GET /api/v1/evidence-quality-workspace`** (collection assurance summary, read-path reliability posture, dimensioned rows); **`GET /api/v1/evidence-weakness-explanation`** (explanation blocks, next-best pivots)
- **WebUI:** **`EvidenceQualityWorkspaceView`**, domain weakness sections, **`navigateToEvidenceQualityWorkspace`**, Overview / NOC **`EvidenceQualityOverviewEntry`**—**not** workflow, approval, or Grafana-owned product semantics
- **NOC / search / briefing:** strategic pivots and cross-surface entry per [`noc-cockpit-contract.md`](./noc-cockpit-contract.md) and [`operator-search-contract.md`](./operator-search-contract.md)
- **Verifier / tests:** structural checks and repository **`vitest`** / **`pytest`** as recorded in **03-CURRENT-STATUS** (including week **39** Friday task **01** alignment where shipped)

## What week 39 did **not** imply

- **No** workflow execution, dry-run APIs, validation engines, safe-to-change verdicts, or approval semantics
- **No** substitute for deep reads on **Evidence consistency**, **Operational stability**, **Maintenance evidence**, **Maintenance window workspace**, **Change safety case**, or **`evidence_export_v1`** when those contracts matter—composition **over** prior weeks, not redefinition
- **No** merge of evidence-quality semantics into **`evidence_consistency_summary_v1`** or **`operational_stability_summary_v1`**—distinct workspaces per contracts
- **No** authorization to extend **`evidence_quality_workspace_v1`**, **`evidence_weakness_explanation_v1`**, **`view=evidence-quality-workspace`**, or week **39** pivot surfaces for polish or feature accretion **without new evidence** of contract drift or a proven gap—**anti-reopen** discipline matches **post-week-32** through **post-week-38** guardrails

## Relationship to post–week 38

[`post-week-38-bounded-phase2-recommendation.md`](./post-week-38-bounded-phase2-recommendation.md) selected **Evidence Quality Workspace / collection assurance** as the next bounded slice after week **38**. **Week 39** implemented that lane **without** reopening week **38** **maintenance window workspace**, **handoff export**, **`mww_subject`**, or **`navigateToStabilityWorkspace`** semantics as backlog—composition **over** weeks **27–39**, not redefinition.

## Scheduling default (evidence-first, **one** slice)

There is **still no automatic default implementation lane** after week **39**.

Pick **one** narrow theme per cycle—**not** parallel defaults:

1. **Evidence-gated truth-depth or ADR cycle** — per [`decisions/ADR-0001-next-bounded-truth-depth-slice.md`](./decisions/ADR-0001-next-bounded-truth-depth-slice.md), [`week-33-evidence-backed-reassessment-memo.md`](./week-33-evidence-backed-reassessment-memo.md), and truth-depth reviews—**or**
2. **Documentation-first** alignment (e.g. topology partiality, operator-boundary drift) only when live lab evidence supports that **single** theme—**or**
3. **Narrow copy/docs-only** follow-on when **wording** drift is proven—per [`week-33-bounded-next-slice-recommendation.md`](./week-33-bounded-next-slice-recommendation.md) (do **not** assume another full labeling cycle is the default)

**Do not** reopen **week 39** evidence-quality workspace, weakness explanation, cross-surface pivots, or NOC/search/briefing integration for momentum; **do not** treat week **39** closure as a backlog invitation for new assemblies.

**No** product scope is prescribed here for a future week—each candidate slice must be **evidence-justified** and Phase **2** safe.

## Explicit anti-recommendations

- **Reopening week 39 surfaces for UX polish or scope creep** without new evidence
- **Parallel** “default” slices (labeling + new assembly + doc churn in one cycle)
- **Phase transition** language or workflow semantics that exceed Phase **2**
- **Grafana** as the product surface for these workspaces ([`dashboards.md`](./dashboards.md))

## References

| Topic | Document |
| --- | --- |
| Operational truth | [`../../agent/sdn/03-CURRENT-STATUS.md`](../../agent/sdn/03-CURRENT-STATUS.md) |
| Roadmap | [`roadmap.md`](./roadmap.md) |
| Post–week 38 (pre–week 39 posture / chosen slice) | [`post-week-38-bounded-phase2-recommendation.md`](./post-week-38-bounded-phase2-recommendation.md) |
| Post–week 37 | [`post-week-37-bounded-phase2-recommendation.md`](./post-week-37-bounded-phase2-recommendation.md) |
| Week 33 next-slice (labeling) | [`week-33-bounded-next-slice-recommendation.md`](./week-33-bounded-next-slice-recommendation.md) |
| Evidence quality workspace | [`evidence-quality-workspace-contract.md`](./evidence-quality-workspace-contract.md) |
| Evidence weakness explanation | [`evidence-weakness-explanation-contract.md`](./evidence-weakness-explanation-contract.md) |
